Keywords: OXiGENE, VaxGen, M&A, Research refoscusing, Zybrestat, Macular degeneration

OXiGENE restructures after failed merger with VaxGen, focusing resources on key programs

Article | 15 February 2010

US cancer and eye disease drug developer OXiGENE has revealed a restructuring plan designed to focus resources on the company's ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in